Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab injection vs Erbitux with mFOLFOX6 in metastatic colorectal cancer
CTR20192102Phase 3Completed
- Sponsor
- Ampoz Biomedical
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cetuximab in metastatic colon cancer (mCRC), sponsored by Ampoz Biomedical. Started Oct 2019; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on CTR20192102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192102.